Wellington Management Group LLP Has $47.83 Million Holdings in Geron Co. (NASDAQ:GERN)

Wellington Management Group LLP lifted its stake in shares of Geron Co. (NASDAQ:GERN - Free Report) by 6.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,510,114 shares of the biopharmaceutical company's stock after buying an additional 847,710 shares during the quarter. Wellington Management Group LLP owned approximately 2.12% of Geron worth $47,826,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in GERN. Barclays PLC lifted its stake in Geron by 114.9% during the third quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company's stock worth $5,902,000 after purchasing an additional 694,931 shares during the last quarter. KBC Group NV lifted its stake in Geron by 45.1% during the fourth quarter. KBC Group NV now owns 24,414 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 7,592 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Geron by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 128,176 shares of the biopharmaceutical company's stock worth $454,000 after purchasing an additional 12,239 shares during the last quarter. Lazari Capital Management Inc. lifted its stake in Geron by 11.7% during the fourth quarter. Lazari Capital Management Inc. now owns 76,424 shares of the biopharmaceutical company's stock worth $271,000 after purchasing an additional 8,000 shares during the last quarter. Finally, abrdn plc lifted its stake in Geron by 24.2% in the fourth quarter. abrdn plc now owns 1,847,285 shares of the biopharmaceutical company's stock valued at $6,539,000 after buying an additional 360,027 shares during the last quarter. Institutional investors and hedge funds own 73.71% of the company's stock.

Geron Stock Up 10.8%

Shares of GERN traded up $0.16 during mid-day trading on Tuesday, reaching $1.59. The company's stock had a trading volume of 6,531,705 shares, compared to its average volume of 11,831,686. Geron Co. has a 1 year low of $1.17 and a 1 year high of $5.34. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -4.95 and a beta of 0.76. The business has a fifty day moving average of $1.38 and a 200 day moving average of $2.41.

Geron (NASDAQ:GERN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. The company had revenue of $39.60 million during the quarter, compared to analyst estimates of $49.88 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The company's revenue for the quarter was up 12927.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.07) EPS. As a group, analysts forecast that Geron Co. will post -0.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GERN has been the topic of a number of research analyst reports. B. Riley lowered Geron from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $3.50 to $2.00 in a report on Thursday, February 27th. Scotiabank lowered Geron from a "sector outperform" rating to a "sector perform" rating and lowered their target price for the stock from $4.00 to $1.50 in a report on Thursday, May 8th. Barclays reaffirmed an "overweight" rating and set a $4.00 target price (down from $9.00) on shares of Geron in a report on Thursday, February 27th. HC Wainwright reaffirmed a "neutral" rating on shares of Geron in a report on Wednesday, March 12th. Finally, Stifel Nicolaus lowered their target price on Geron from $8.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $5.06.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.